Showing 4691-4700 of 9406 results for "".
- Incyte and Mandy Moore Partner to Empower People with AD in New Campaignhttps://practicaldermatology.com/news/incyte-and-mandy-moore-partner-to-empower-people-with-ad-in-new-campaign/2462060/Actress, singer and songwriter Mandy Moore is partnering with Incyte on
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantl
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Co
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R),
- Professor Alexander Egeberg Named Head of Global Medical Affairs at Leo Pharmahttps://practicaldermatology.com/news/professor-alexander-egeberg-named-will-head-of-global-medical-affairs-at-leo-pharma/2462050/Professor Alexander Egeberg is LEO Pharma’s new Vice President, Head of Global Medical Affairs. The announcement was made ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress. Alexander Egeberg joins LEO Pharma from his role as professor of de
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- Antibiotic-induced Acute Generalized Exanthematous Pustulosis: A Case Study of an 18-year-old Pregnant Female Presenting with Fever, Tachycardia, and Pustular Skin Eruptionhttps://practicaldermatology.com/news/antibiotic-induced-acute-generalized-exanthematous-pustulosis-a-case-study-of-an-18-year-old-pregnant-female-presenting-with-fever-tachycardia-and-pustular-skin-eruption/2462046/On the day of giving birth via vaginal delivery complicated by intrauterine fetal demise, an 18-year-old female, G1P000, developed preeclampsia with severe features. The patient subsequently developed chorioamnionitis and was started on ampicillin-gentamicin. After administration of the antibioti
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in